Could a more coordinated EU HTA improve access to new healthcare technologies, favour development of EU-wide evidence development infrastructure and reduce fragmentation? These and other related topics will be discussed on July 9th in Brussels in a meeting organised by the EU Commission and that will involve relevant stakeholders. Here below a link to the meeting webpage:
June 1st 2018 – The German G-BA has started the procedure for the benefit assessment of Takeda (Tigenix) Alofisel®️ (darvadstrocel). The publication of the benefit assessment is expected on September 3rd and a final resolution end of November 2018.
link to G-BA webpage
We need to think at new ways to fund general population screening programs
link to article
link to Nature article
An interesting contribution to the gene therapy pricing debate from Professor Maria Kefalas, mother of Calliope Joy Carr, a child affected by metachromatic leukodystrophy. Please click on link below to read the original article
Link to the original article on STAT